Type | Public company |
---|---|
Nasdaq: PSDV ASX: PVA FWB: PV3 | |
Industry | Pharmaceuticals |
Headquarters | , |
Number of locations | 2 |
Products | Iluvien |
Website | www |
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) pSivida is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ).[citation needed] QinetiQ continues to be a strategic partner.[1][2]
In June 2004, pSivida acquired full ownership of pSiMedica.[1] In April 2018, pSivida purchased eye products firm Icon Bioscience.[3][4]
YouTube Encyclopedic
-
1/2Views:1 138349
-
PANCREATIC CANCER BREAKTHROUGH
-
AAO TV Sunday Highlights From AAO 2016
Transcription
See also
- Alimera Sciences, pSvida's partner on Iluvien
References
- ^ a b "PSivida lifts pSiMedica stake to 100%". The Sydney Morning Herald. 2004-06-02. Retrieved 2020-10-29.
- ^ . 2004-06-18. Retrieved 2020-10-29.
- ^ "BRIEF—pSivida to buy eye products firm Icon Bioscience". The Pharma Letter. Retrieved 2018-06-22.
- ^ "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience". Reuters. 2018-03-28. Retrieved 2020-10-29.
External links
- Official website
- "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. Retrieved May 15, 2015.
- pSivida Mesoporous silicon patent